Overview and Scope
Merkel cell carcinoma (MCC) treatment refers to the treatment of a condition for a rare and aggressive form of skin cancer that typically develops on sun-exposed areas of the skin, such as the head, neck, and arms. It arises from Merkel cells, which are specialized cells responsible for detecting light, touch, and pressure.
Sizing and Forecast
The merkel cell carcinoma treatment market size has grown strongly in recent years. It will grow from $3.38 billion in 2023 to $3.56 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to rising incidence of merkel cell carcinoma cases, patient and physician awareness, rising treatment options, rise of combination therapy.
The merkel cell carcinoma treatment market size is expected to see steady growth in the next few years. It will grow to $4.24 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to rise of targeted therapys, improved diagnostic techniques, growing use of precision medicine, the rise of personalized medicine. Major trends in the forecast period include advancements in early detection, development of new drug delivery systems, increasing use of biomarkers to diagnose, immunotherapy advancements, growing digital health technologie.
To access more details regarding this report, visit the link:
Segmentation & Regional Insights
The merkel cell carcinoma treatment market covered in this report is segmented –
1) By Diagnosis: Physical Examination; Sentinel Node Biopsy; Imaging Test
2) By Therapy: Surgical Excision; Micrographic Surgery; Radiation; Chemotherapy; Other Therapies
3) By Route Of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Centers; Other End Users
Asia-Pacific was the largest region in the merkel cell carcinoma treatment market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in merkel cell carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12868&type=smp
Major Driver Impacting Market Growth
The increasing incidence rate of skin cancer cases is expected to propel the growth of the Merkel cell carcinoma treatment market going forward. Skin cancer describes a particular type of cancer that starts in the skin cells. It occurs when normal cells in the skin undergo genetic mutations that cause them to grow uncontrollably and form malignant tumors. Merkel cell carcinoma (MCC) and skin cancer are closely related, Merkel cell carcinoma is a rare and aggressive type of skin cancer that typically arises from Merkel cells, which are specialized skin cells involved in touch sensation. For instance, in January 2023, according to the American Cancer Society Inc., a US-based voluntary health organization, there were around 97,610 new melanoma cases and 7,990 people are expected to die in 2023 in the US. Furthermore, in July 2022, according to Melanoma UK, a UK-based charity organization, according to the WHO (World Health Organization), by 2025, there will be 9% more cases of melanoma skin cancer and nearly 22,886 people will be diagnosed with melanoma skin cancer by 2040. Therefore, the increasing incidence rate of skin cancer cases is driving the growth of the Merkel cell carcinoma treatment market.
Key Industry Players
Major players in the merkel cell carcinoma treatment market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche AG, Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ono Pharmaceutical Co Ltd., Millennium Pharmaceuticals Inc., Seattle Genetics Inc., Lupin Ltd., BeiGene Ltd., Siemens AG, Canon Medical Systems Corporation, NantKwest Inc., Immune Design Corporation, Oncovir Inc., ImmunityBio Inc., OncoSec Medical Inc.
The merkel cell carcinoma treatment market report table of contents includes:
1. Executive Summary
2. Merkel Cell Carcinoma Treatment Market Characteristics
3. Merkel Cell Carcinoma Treatment Market Trends And Strategies
4. Merkel Cell Carcinoma Treatment Market – Macro Economic Scenario
5. Global Merkel Cell Carcinoma Treatment Market Size and Growth
.
.
.
26. South America Merkel Cell Carcinoma Treatment Market
27. Brazil Merkel Cell Carcinoma Treatment Market
28. Middle East Merkel Cell Carcinoma Treatment Market
29. Africa Merkel Cell Carcinoma Treatment Market
30. Merkel Cell Carcinoma Treatment Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Johnson & Johnson Private Limited
- F. Hoffmann-La Roche AG
- Janssen Pharmaceuticals Inc
- AbbVie Inc
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
